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Abstract
Squamous cell carcinoma (SCC) of the lung kills over 350,000 people annually worldwide, and is the main lung cancer
histotype with no targeted treatments. High-coverage whole-genome sequencing of the other main subtypes, small-cell
and adenocarcinoma, gave insights into carcinogenic mechanisms and disease etiology. The genomic complexity within the
lung SCC subtype, as revealed by The Cancer Genome Atlas, means this subtype is likely to benefit from a more integrated
approach in which the transcriptional consequences of somatic mutations are simultaneously inspected. Here we present
such an approach: the integrated analysis of deep sequencing data from both the whole genome and whole transcriptome
(coding and non-coding) of LUDLU-1, a SCC lung cell line. Our results show that LUDLU-1 lacks the mutational signature that
has been previously associated with tobacco exposure in other lung cancer subtypes, and suggests that DNA-repair
efficiency is adversely affected; LUDLU-1 contains somatic mutations in TP53 and BRCA2, allelic imbalance in the expression
of two cancer-associated BRCA1 germline polymorphisms and reduced transcription of a potentially endogenous PARP2
inhibitor. Functional assays were performed and compared with a control lung cancer cell line. LUDLU-1 did not exhibit
radiosensitisation or an increase in sensitivity to PARP inhibitors. However, LUDLU-1 did exhibit small but significant
differences with respect to cisplatin sensitivity. Our research shows how integrated analyses of high-throughput data can
generate hypotheses to be tested in the lab.
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Introduction
Lung cancer kills more people than colorectal, prostate and
breast cancer combined [1]. Squamous cell carcinoma (SCC)
constitutes 26% of all lung cancer [2], making it one of the main
histological subtypes besides small-cell and adenocarcinoma.
Karyotypes of lung SCCs have revealed some commonality in
the genomic landscape of these tumours, including distal
amplification of 3q [3] and a more focal amplification at 8p12
[4], but as yet these findings have not translated into the clinic.
SCC remains the most common lung cancer histotype for which
no genomically targeted therapy currently exists [5]. The lack of
such therapy prompted inclusion of the lung SCC subtype in The
Cancer Genome Atlas (TCGA) project, an international collab-
oration aimed at cataloguing cancer-driving genetic variation
within tumours using multiple high-throughput approaches. One
such approach was Next-Generation Sequencing (NGS), which
has been used to gain insights into disease development and
progression in several types of cancer, including both lung
adenocarcinoma and small-cell lung cancer (SCLC) [6,7]. The
results of TCGA study of SCC revealed marked genomic
complexity within lung SCC patient samples. However, path-
way-specific alterations, hoped to yield therapeutic targets, did
cluster by expression subtype, indicating the importance of
integrating transcriptomic information in order to understand
the phenotypic consequences of the plethora of genomic changes
[8]. To understand how a more detailed, integrated analysis may
aid inspection of lung SCC genomes, we deeply sequenced both
the genome and transcriptome of LUDLU-1: a lung SCC cell line
derived from a male patient whose smoking status is unknown. We
also sequenced appropriate controls: the genome of an EBV-
transformed lymphocyte cell from the same patient (cell line
AGLCL) and the transcriptome of a normal bronchial epithelial
cell line (LIMM-NBE1). To maximize our findings, we adopted an
RNA sequencing method that captured both coding and non-
coding RNA in a manner that retained information regarding the
strand of origin. We have previously catalogued the transcriptional
consequences of somatic structural variants in this cell line but
here we focus on point mutations, aiming to see whether the
mutational signature would give insight into disease etiology or
carcinogenic mechanism, as it has for other cancer subtypes
[6,9,10]. This type of in-depth characterisation of a given tumour
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can result in new hypotheses that can be tested using functional
assays.
Materials and Methods
Cell Lines
LUDLU-1 and AGLCL were cultured as we have indicated
previously [10]. LUDLU-1 was shown to be p63 positive and
TTF-1 negative (data not shown) confirming a squamous
carcinoma subtype. A549 was obtained from American Type
Culture Collection (ATCC; Manassas, USA) and cultured in
Advanced DMEM-F12 medium (Life Technologies, 1263-4010)
supplemented with 5% foetal bovine serum (Sigma, F7524), 2 mM
GlutaMAXTM (Life Technologies, 3505-0087) and 50 U/ml
penicillin and 50 mg/ml streptomycin (Life Technologies, 15070)
at 37uC with 7.5% CO2.
DNA/RNA Extraction, Sequencing and Alignment
This was performed as previously described in Stead et al. [10].
Briefly, Complete Genomics used their proprietary method to
sequence DNA that we extracted from the LUDLU-1 and
AGLCL cell lines. RNA, extracted from LUDLU-1 and LIMM-
NBE1, was sequenced by LGC Genomics on an Illumina HiSeq
2000 using 50 bp single end reads. Sequenced reads were aligned
to the human reference genome, build 37, except in the case of
miRNAs which were aligned to known miRNAs from build 36
using miRanalyzer [11]. All sequencing data have been submitted
to the NCBI sequencing read archive (SRA: http://www.ncbi.
nlm.nih.gov/sra) under accession numbers ERP001465 (LUDLU-
1 and LIMM-NBE1 RNA sequencing) and ERP001771 (LUDLU-
1 and AGLCL DNA sequencing).
Mutation Detection
Complete Genomics call and score genomic variants during
their local de novo assembly approach and output results into
variant files, two of which (i.e. the tumour sample and matched
normal) are compared, to identify somatic variants, using a tool
called calldiff that is included in their proprietary cgatools 1.5.0,
build 31, software suite. Somatic variants are each annotated with
a somatic score [12]. Structural variants were extracted from the
Junctions files, provided as part of the Complete Genomics
sequencing report. Somatic mutations have been submitted to
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) under the handle
LIMM_YCR_PGG.
Mutation Validation
50 coding and 50 non-coding single somatic variants were
selected at random, and checked to ensure a normal distribution of
somatic scores had been captured. Primer design failed for four
but 96 underwent PCR and capillary sequencing, with seven
giving ambiguous results. A receiver operating characteristic
(ROC) curve was created using the validation results from the
remaining 89 variants (data not shown), enabling us to set the
somatic score threshold for single substitutions at 0.084, resulting
in an estimated 100% specificity and 84% sensitivity. Indel
validation was unsuccessful owing to ambiguous PCR/capilliary
sequencing read-outs so all variants of this type were included if
they had a somatic score .0. Somatic structural variants were
validated as described in Stead et al. [10].
Expression Analysis
Performed as described in Stead et al. [10]. Briefly, the number
of reads aligning to exons, annotated as per Ensembl 60 [13], were
counted and normalised by gene length and total number of
mapped reads, resulting in a per gene expression metric: Reads
Per Kilobase per million Mapped (RPKM). Reads that had
between two and five valid alignments were assigned a single
location using SEQEM [14].
Single Somatic Mutation Analysis
A subset of 5% (108,362) of the germline polymorphisms in
LUDLU-1 were selected, at random, for comparison with the
somatic variants. All single nucleotide substitutions were annotated
using a bespoke script that accessed Ensembl 60 via its Perl
application programming interface. Additional information on the
location of CpG islands was downloaded from the UCSC genome
browser and incorporated into our in-house code. Pathogenicity
scores were attained from MutPred [15]. Variable distributions or
count data were tested between samples, or variant type, using an
appropriate significance test (Wilcoxon and Chi-squared or
Fisher’s Exact respectively) at the 5% level but corrected for
multiple testing using the Bonferonni correction.
Allele counts for heterozygous variants were attained for both
the genome and the transcriptome using SNVmix2 [16] (once
Complete Genomics data had been converted using the cg2bam
tools provided in the cgatools package). Allelic imbalance was
tested only in those genes deemed as expressed in the tumour or
normal and we required that a 10% change in absolute allele
frequency been seen for either the DNA or RNA data, as per Tuch
et al., 2010 [17]. Ratios were tested using Fisher’s exact test at a
false discovery threshold of 5%.
To assess transcription-coupled repair, we used Cufflinks [18] to
delineate transcripts within our LUDLU-1 RNAseq data, guided
by Ensembl 60 gene annotations. The output included the strand
each gene was located on. We recorded the number of mutations
in each annotated, expressed gene, and whether each was on the
transcribed or non-transcribed strand. We then calculated the rate
of mutations per at risk base in the gene footprint. Significance
(5% level with Bonferroni correction) and curve-fitting was
performed using a zero-inflated, negative binomial regression
model in R.
Drugs
Cisplatin was purchased from Sigma (P4394), dissolved in
dimethyl sulfoxide (DMSO) at 3.3 mM and stored at 220uC.
Proliferation Assays
A flask of subconfluent cells was trypsinised; recovered cells
were washed once with PBS and then seeded in culture medium at
a density of 1,000 to 4,000 cells per mL in 96 well plates. The
plates were incubated at 37uC with 7.5% CO2 overnight to allow
cells to adhere. Treated culture medium was prepared at a 2X
concentration and 100 ml was added to each well. The cells were
then treated with one of six concentrations of cisplatin (0. 3125,
0.625, 1.25, 2.5, 5, 10 mM) or the control (DMSO). The plates
were incubated for a further 5 days. At this point the cells were
stained with crystal violet, allowed to dry and 100 mL of 33%
glacial acetic acid was added. The absorbance was read at 590 nm
using the POLARstar OMEGA plate reader. IC50 values were
calculated using Calcusyn V2 software (Biosoft, Cambridge, UK).
Cell line sensitivity to cisplatin was compared by ANOVA using
SPSS Statistics v19 (IBM). Cisplatin was purchased from Sigma
(P4394), prepared at 3.3 mM in DMSO and stored at 220uC.
Clonogenic Survival Assay
The method was as described by Grenman et al [19]. In brief, a
flask of subconfluent cells were trypsinised, washed once with PBS
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and seeded in culture media at a starting density of 1,200 cells per
well in 96 well plates. A 1 in 10 serial dilution was made for A549
cells and for LUDLU-1, a 1 in 5 serial dilution was carried out.
The plates were incubated at 37uC with 7.5% CO2 for 2 hours
and then cells were exposed to 2, 4, 6 and 6 Grays of 137Cs
(10 Gy, 1.958 Gy/min) in a GSR-D gamma irradiator. Plates
were incubated for a further 7 to 14 days until colonies reached a
size of 32 cells or more. Plating efficiency (PE) was calculated as
described by Thilly et al [20] using Poisson statistics according to
the formula PE = -In (neg wells/total wells)/number of cells plated
per well. The fraction survival was expressed relative to the PE of
the un-irradiated control. Radiation survival curves were com-
pared by linear regression using SPSS Statistics v19 (IBM) as
previously described [21].
Results
We sequenced the LUDLU-1 genome to an average coverage of
61x (i.e. each base was sequenced, an average, 61 times), and the
matched lymphocyte to an average 55x. Copy number analysis
shows that the SCC cell line is largely tetraploid and shares several
features previously seen in lung SCC [10].
We identified 31,141 somatic single base substitutions (Supp.
Table A in File S2), on average 10 per megabase (Mb). This
exceeds the average mutation rate of 8.1 per Mb, ascertained from
the sequencing of 178 lung SCC exomes as part of TCGA project
in clinical samples [8]. A total of 181 somatic substitutions were
located within coding regions of LUDLU-1 compared to an
average of 360 in the series included in TCGA (Table 1). This
included the only somatic mutation in the tumour cell line that is
present in the Catalogue Of Somatic Mutations In Cancer
(COSMIC) of clinical tumours [22]: a non-synonymous variant in
TP53 (ID:10656). This somatic mutation causes Arg248Trp; this is
highly likely to inactivate the tumour-supressor function of p53, a
protein involved in DNA repair, by removing the ability of Arg248
to directly contact the DNA response element via the minor
groove [23]. No wild-type allele is present, as confirmed by the
transcriptome sequencing. This specific p53 variant has been
shown to be a gain-of-function mutation that promotes tumori-
genesis [24].
We discovered 9431 somatic structural variants ranging from
.1 bp substitutions to chromosomal translocations (Table 2 and
Supp. Tables B and C in File S2). Included in the list of genes
affected by structural variants is BRCA2, a tumour suppressor gene
encoding a protein that repairs double-stranded (ds)DNA breaks
by homologous recombination [25]. Therein a heterozygous single
base deletion causes a frameshift anticipated to result in a
dysfunctional protein product.
LUDLU-1 Lacks the Mutational Signature Previously
Associated with Tobacco Exposure
The smoking status of the LUDLU-1 donor is unknown.
Previously, the smoking status of a small cell lung cancer cell line
donor was assigned via the presence of a mutational signature of
tobacco exposure [6]. This signature consists of an excess of G.T
mutations, where G.T denotes a GC base pair being mutated to a
TA base pair, and has been observed in both SCLC (34%
prevalence) and lung adenocarcinoma (46% prevalence) whole
genome sequencing data [6,7,26–29]. In contrast, the most
common variants in LUDLU-1 were A.G (26%), and G.A
transitions (24%). This implies that the LUDLU-1 somatic profile
is not consistent with a smoking-based etiology for this lung SCC.
However, to date, the smoking-associated somatic signature has
not been validated on a genome-wide basis for lung SCC. We,
therefore, downloaded data on 123,778 somatic mutations
identified as part of TCGA study into clinical lung SCCs [8].
These somatic mutations originated from 163 current or previous
smokers, and 7 lifelong never-smokers. Surprisingly, we found that
G.T transversions were the most prevalent mutation subtype in
Table 1. The consequence of LUDLU-1 somatic substitutions.
Consequence/Type Variants Transcripts affected Genes affected
STOP_LOST 1 2 1
STOP_GAINED 3 4 3
UPSTREAM (59+5 kb) 2100 3090 1749
DOWNSTREAM (39+5 kb) 2202 3140 1822
SYNONYMOUS_CODING 52 149 44
NON_SYNONYMOUS_CODING 106 267 89
SPLICE_SITE 1–3 bps into an exon or 3–8 bps into an intron 19 48 21
ESSENTIAL_SPLICE_SITE First or last 2 bps of an intron 6 29 6
39UTR 137 229 126
59UTR 47 70 43
INTRONIC 11021 15822 4109
INTERGENIC 17642 NA NA
doi:10.1371/journal.pone.0078823.t001
Table 2. Structural somatic variants identified in LUDLU-1.
Somatic Variant Total Within/affecting genes
Substitutions (.1 bp) 584 41
Insertions 4054 57
Deletions ,= 100 bp 2622 32
Deletions .100 bp 66 42
Inversions 47 18
Duplications 29 18
Translocations 29 15
doi:10.1371/journal.pone.0078823.t002
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both groups, with a significantly higher proportion in the never-
smokers compared to the smokers (35% versus 33%: x2,
p = 2.461025). We compared the distribution of G.T mutation
proportions across the two groups and found no significant
difference (Wilcoxon, p = 0.93). Tobacco carcinogens cause
CpG.T transversions more frequently at methylated CpG
dinucelotide [30] resulting in an expected increase in somatic
CpG.T mutations outside of CpG islands, where 65% of CpGs are
methylated compared to 15% within islands, in smokers. In
contrast to this, the same proportion of somatic CpG.Ts were
observed inside and outside of CpG islands in both the smoker and
never-smoker groups from TCGA lung SCC data (Wilcoxon,
p = 0.86). Hence, the mutational profile of tobacco exposure is a)
lacking in LUDLU-1, and b) not seen exclusively in lung SCC
tumours from smokers, according to TCGA data. We examine
these results further in our discussion section.
Sequencing the Transcriptome of a Lung SCC
We sequenced total RNA, after ribosomal RNA depletion, using
a strand-specific method that enabled us to quantify both protein-
coding and non-coding (nc)RNAs. To investigate tumour-specific
expression patterns we first required a baseline of transcription in
the appropriate non-diseased tissue, so we also sequenced a
normal bronchial epithelial cell line that we established in-house
and named LIMM-NBE1. A total of 600.4 million LUDLU-1
RNA reads aligned to the human reference genome; of these
87.5% (525.4 million) aligned uniquely, and an additional 168,546
small RNA (,20 bp) reads aligned to known miRNAs. Results
were similar for LIMM-NBE1, where 700.8 million RNA reads
aligned, of which 88.2% (618 million) did so uniquely, likewise a
further 184,740 small RNA reads aligned to known miRNAs. To
verify that the transcriptional profile of LIMM-NBE1 was
characteristic of a bronchial epithelial cell, we inspected 27 genes
listed on the Tissue Specific Gene expression Database (TiSGeD)
as being highly bronchial epithelial cell-specific. There were
sequenced RNA reads supporting each of these 27 genes in
LIMM-NBE1; 24 (89%) exceeded the 10 RPKM threshold we
used to denote expression and all but one of those exhibited above
median expression in LIMM-NBE1 compared with all non-zero
RPKM protein-coding genes [31]. This indicates that LIMM-
NBE1 has a characteristic transcriptional profile for a bronchial
epithelial cell. We performed the same analysis in LUDLU-1 and
found that 23 of the 27 genes (85%) exceeded the RPKM
threshold for expression and all but two of those exhibited above
median expression in LUDLU-1 compared with all non-zero
RPKM protein-coding genes. This indicates that LUDLU-1 did,
indeed, originate in the lung.
Additional Evidence of DNA Repair Deficiency
We used our RNA data to quantify expression in Reads Per
Kilobase per million Mapped reads (RPKM), allowing us to
inspect the relative abundance of each functional transcript class
and to identify the transcripts, within each class, that exhibited the
largest fold change in expression between the normal and the
tumour (Supp. Table D in File S2). Interestingly the largest fold
change was not for a protein-coding gene but an antisense gene
called RPPH1.1 (Ensembl ID ENSG00000259001) that appears
not to be expressed in the tumour but exhibits an RPKM of
13,194 in the bronchial epithelium; this gene is antisense to
PARP2. Expression of PARP2 itself shows only modest differences
between our samples (62 RPKM in LUDLU-1 and 98 in the
normal) but antisense transcripts can regulate their mRNA
counterparts post-transcriptionally, most often, though not exclu-
sively, resulting in decreased protein levels [32,33]. Consequently,
reduced antisense transcription may lead to increased levels of
protein product of PARP2, a DNA repair gene, in LUDLU-1.
We proceeded to integrate our datasets to investigate the
incidence of allelic imbalance (AI), the unequal expression of two
alleles at a heterozygous locus. AI is commonly observed in cancer
as a result of genomic alterations such as copy number changes
and loss of heterozygosity. We wished to investigate the situation
when one allele is preferentially expressed owing to other
mechanisms such as epigenetic changes affecting, or mutations
within the regulatory regions of, one allele only. We were able to
do this by identifying those heterozygous variants within our
tumour cell line that had a significantly different allelic ratio in the
RNA compared to the DNA sequencing data, acknowledging that
this will indicate the presence, but not the cause, of the
phenomenon. Of the 180,985 expressed heterozygous variants in
LUDLU-1, 2.1% (3792) exhibit significant AI, affecting 1949
genes. Significantly more cancer genes [34,35] contained one or
more alleles that exhibit AI than would be expected by chance (x2,
p = 2.861025), implying a role for this type of regulation in
carcinogenesis. In total, 143 of the variants with AI are non-
synonymous, with one being somatic and three being germline but
located within cancer genes, as summarised in Table 3. We note
that two non-synonymous, germline BRCA1 variants in LUDLU-1
have imbalanced expression in favour of the mutant allele. In both
cases the mutant allele is a genetic modifier of breast cancer risk
[36–38], indicating that the resulting protein is altered in a manner
that, whilst not able to cause disease in isolation, creates a
predisposition. BRCA2, like BRCA1 is a gene that has been causally
linked to both breast and ovarian cancer. Both genes encode
proteins that are involved in the repair of dsDNA breaks.
Our findings highlighted several alterations in DNA-repair
genes, leading us to further inspect the imprint of expression-
linked repair in our data.
Table 3. LUDLU-1 non-synonymous variants that are either somatic (first row) or germline but in cancer-associated genes (last 3
rows).
Variant Genomic
Coordinate Gene dbSNP ID
Base
variant
Amino acid
variant
DNA ref:var
allelic ratio
RNA ref:var
allelic ratio
Chr7:99056827 ATP5J2 N/A (somatic) T.C T61A 32:24 992:19
Chr17:41244000 BRCA1 rs799917 T.C K1183R 18:12 9:33
Chr17:41244936 BRCA1 rs16942 G.A P871Q 31:25 7:29
Chr3:158320703 MLF1 rs77911695 C.A P201T 36:10 2015:155
doi:10.1371/journal.pone.0078823.t003
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Genome-wide, Transcription-coupled DNA Repair
Transcription-coupled repair (TCR) in a SCLC was recently
investigated by ascertaining the expression levels of genes
harbouring somatic mutations using microarrays, and annotating
expressed variants as being on the transcribed or non-transcribed
strand, according to Ensembl gene annotations [6]. We wished to
expand this analysis by looking at genome-wide expression,
including that of novel transcripts assembled directly from our
RNAseq data. Fig. 1A shows that, in accordance with previous
findings, we observed more purine mutations on the non-
transcribed than the transcribed strand; we found, however, the
reverse to be true for G.A transitions. This indicates that TCR is
in effect but, in the latter case, acting on the pyrimidine i.e. repair
of C.T on the transcribed strand. We proceeded to investigate
how gene mutation rates i.e. the number of mutations per at-risk
base within a gene, alter with expression for each specific
mutation. Here, our results different greatly from previous findings
(Fig. 1B). We observed that mutation rates significantly change
with gene expression for all types of variant, but that for A.T and
A.C on the transcribed strand, and A.G regardless of strand.
This relationship is positively correlated: an increased mutation
rate is observed at higher expression levels. As the SCLC cell line
analysis used Affymetrix U133A arrays, containing probes for
14,500 well-characterised human genes, 98% of which are
protein-coding [6], we repeated our analysis using only protein-
coding genes (Supp. Figure A in File S1). The resulting trends
appear, overall, more similar to those that were previously seen
but we did still observe an increase in mutation rate with
increasing gene expression for C.T on the transcribed strand (i.e.
G.A on the non-transcribed strand). These results imply that
DNA repair mechanisms act differently between protein-coding
and non-coding genes and suggest a potential reduction in the
efficiency of TCR in LUDLU-1.
Functional Assays
To examine the DNA-repair functionality of LUDLU1 we
determined the cell-line’s sensitivity to cisplatin and radiation
relative to another non-small cell lung cancer (NSCLC) cell line,
A549, which is diploid for the BRCA1 locus and wild type for TP53
[39]. In a 5-day proliferation assay LUDLU-1 has a 1.5 fold lower
IC50 for cisplatin than A549 (1.660.4 and 2.560.8 mM,
respectively) (Fig. 2A.). Whilst this is only a small change, the
proliferation dose response was significantly different (p,0.01,
ANOVA) between the cell lines. Pairwise comparisons of cell lines
showed significant differences (p,0.001) between proliferation at
doses of 0.625, 1.25 and 2.5 mM.
Clonogenic survival assays (Fig. 2B) showed a statistically
significant difference in the radiation survival curves of the two cell
lines (p = 0.011), although the difference was modest (90% cell
killing at 4.8 Gy and 6.1 Gy for A549 and LUDLU-1, respec-
tively) and was only clearly apparent at doses above 4 Gy. We also
tested the effect of PARP inhibitors but found no alteration in
sensitivity (IC50.10 mM, data not shown).
Discussion
Tobacco smoke is the main risk factor associated with lung
cancer, accounting for 70–75% of worldwide incidence [1].
However, incidence of lung cancer diagnoses in never-smokers is
increasing in several countries [40,41]. If classified as a separate
sub-type, lung cancer in never-smokers would be ranked as the 7th
biggest cancer killer worldwide [42]. Research indicating that lung
cancer in never-smokers constitutes a biologically distinct form of
the disease has led to increased interest in this subpopulation as an
understanding of its etiology may provide therapeutic targets, as is
the case in adenocarcinoma [42–45]. We attempted to use a
previously identified mutational signature of tobacco exposure
[6,26] to assign the smoking status of the lung SCC cell line
originator patient. Whilst we found that LUDLU-1 lacked this
signature, to our surprise we found that the somatic mutational
profiles from never-smokers within TCGA data did not. This
raises three possibilities. Firstly, the seven never-smokers in TCGA
dataset have not been accurately annotated with regards their
smoking status. Alternatively, the signature (i.e. G.T transver-
sions as the predominating somatic mutation with altered
proportions inside and outside of CpG islands) is not a
consequence of exposure to tobacco carcinogens in lung cancers.
Or, finally, there are biological mechanisms unique to this SCC
line, and perhaps SCC clinically, that underlie the ‘‘signature’’
being associated with something other than tobacco exposure. The
Figure 1. Expressed LUDLU-1 somatic mutations according to
strand. a) The number of expressed mutations that appear on the
transcribed strand (TS) or non-transcribed strand (NTS); b) The
relationship between gene expression and mutation rate (mutations
per Mb of at-risk bases in the gene footprint) for each mutation
according to strand.
doi:10.1371/journal.pone.0078823.g001
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smoking status of patients from whom TCGA samples were
acquired was self-reported; there is evidence of misclassification
with such annotation [46,47]. However, in order to ascertain how
our findings affect the validity of a smoking-associated somatic
mutational signature will require larger cohorts in which somatic
mutations have been identified. We are, thus, unable to conclude
the smoking status of the originator of the LUDLU-1 cell line, but
cannot rule out an alternative etiology for this cancer. Whilst this
manuscript was under review, a paper was published that
describes signatures of mutational processes in cancer [48]. We
compared the LUDLU-1 profile to those within that publication
and found significant similarity with signature 5 (Supp. Figure B in
File S1). Signature 5 was found in 93% of .150 lung squamous
cell tumours tested, but often alongside signature 4, which
significantly correlates with tobacco exposure. The etiology of
signature 5 is unclear; there was some association with tobacco
exposure but it was also prevalent in 7 other non smoking-
associated cancers. The dominance of signature 5 in the LUDLU-
1 somatic mutation profile (Supp. Figure B in File S1) suggests that
it may be a good cell line model for testing the potential causes and
consequences of this mutational profile of unclear origin.
Our approach was to perform an integrated analysis of the
genome and transcriptome, as this can offer greater insight into
pathogenic mechanisms than independent analysis of either
dataset [49,50]. Several findings implied that the LUDLU-1
genome has developed DNA-repair deficiency via a variety of
mechanisms. A somatic substitution in LUDLU-1 is likely to lead
to p53 inactivation. Knocking out Trp53, the ortholog in mice,
does not directly cause cancer but increases the likelihood of
spontaneous tumour formation [51] owing to defective DNA
repair or apoptosis. A somatic deletion in LUDLU-1 is suspected
to deactivate one copy of BRCA2. Being heterozygous, this
deletion is unlikely to have caused the cancer in isolation, but
could contribute to the formation of a defective DNA repair
background. Similarly, allelic imbalance in favour of mutant
BRCA1 containing 2 germline variants associated with cancer risk
could contribute to a DNA-repair deficient phenotype. Finally, we
found reduced expression of a potential endogenous PARP2
inhibitor. Genomic abnormalities resulting in loss of DNA repair
function are associated with the development of several tumours,
i.e. loss of BRCA1 or BRCA2 genes in hereditary ovarian or breast
cancer [52–54], or defects in the DNA mismatch repair pathway
in hereditary non-polyposis colorectal cancer [55]. In these
tumours an alternative pathway(s), which may not be as effective,
compensates the defect in an individual repair gene/pathway. This
vulnerability makes these cancers more sensitive to therapies that
inhibit DNA repair. To test if this was the case in LUDLU-1, we
performed functional assays to assess cisplatin, PARP-inhibitor
and radiation sensitivity, compared to a control lung cancer cell
line. Whilst no changes were seen in the latter two, a modest but
significant increase in cisplatin sensitivity was observed. Platinum-
based chemotherapy regimes are a mainstay in the treatment of
non-small cell lung cancer. However, treatment failure is often
observed and is believed to be, in part, because of the upregulation
of DNA repair pathways, which remove adducts caused by the
platinum-based treatment [56,57]. Tumour cells with BRCA loss
have been reported to be ten to one hundred times more sensitive
to cisplatin, PARP inhibitors and radiation [58]. The lack of radio-
sensitivity and PARP insensitivity in LUDLU-1 cells suggest that
the remaining wild-type copies of BRCA genes in this cell line
provide sufficient functionality, or that alternative pathways can
fully compensate for the heterozygous loss of functional BRCA1
and increase in a single BRCA2 allele, in response to these specific
treatments. However, a deficiency in DNA-repair is apparent, and
incompletely compensated to increase cisplatin-induced cell
killing. This indicates that LUDLU-1 provides a good model for
further experimentation into DNA repair phenotypes in the lung
SCC subtype, the results of which can be evaluated in light of the
DNA and RNA sequencing data provided.
The value of whole genome sequencing has been questioned
when exon sequencing, possible with much larger sample
numbers, can deliver tumour markers and drug targets [59].
However, our in-depth cross-platform analysis of a single sample
has allowed us to speculate on underlying mechanisms of
tumourigenesis and predict that hyper-mutation was caused by
DNA-repair deficiencies.
Supporting Information
File S1 Supplemental Figure A. Expressed LUDLU-1
somatic mutations within protein-coding genes accord-
ing to strand. a) The number of expressed mutations that
appear on the transcribed strand (TS) or non-transcribed strand
(NTS); b) The relationship between protein- coding gene
expression and mutation rate (mutations per Mb of at-risk bases
in the gene footprint) for each mutation according to strand.
Supplemental Figure B. Mutational profiles for A)
LUDLU_1, and B) Somatic Mutation Signature 5 as
assigned in Alexandrov et al, Nature 2013 ‘‘Signatures of
Figure 2. Molecular functionality testing of LUDLU-1. a) The
effect of increasing dose of cisplatin on the cell proliferation of LUDLU-1
and A549; b) The survival fraction of LUDLU-1 and A549 when
irradiated. Proliferation data is representative of duplicate independent
experiments, with significance p values of less than 0.001. Radiation
sensitivity data is representative of triplicate independent experiments.
doi:10.1371/journal.pone.0078823.g002
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mutational processes in human cancer.’’. The 6 main
substitution types are shown in different colours, broken down by
sequence context i.e. one base either side of the mutated base. This
shows how consistent the LUDLU-1 mutational profile is with
signature 5. The lower image is reprinted by permission from
Macmillan Publishers Ltd: Nature, copyright 2013.
(PDF)
File S2 Supplemental Table A. Somatic point mutations in
LUDLU-1. Supplemental Table B. Somatic insertions (ins),
deletions (del) and substitutions (sub) in LUDLU-1 that range from
2–99 bp. Supplemental Table C. Somatic structural variations
in LUDLU-1including deletions .99 bp. Supplemental Table
D. Expression levels in RPKM (Reads Per Kilobase per Million
reads mapped) for the top 10 genes per functional transcript class
that showed the largest increase or decrease between normal and
tumour in terms of fold change.
(XLSX)
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